Results 201 to 210 of about 86,485 (257)

The use of JAK inhibitors and tocilizumab in the management of TRAPS: a sibling case study. [PDF]

Pediatr Rheumatol Online J
Thai D, Tiller G, Akikusa J, Taranto M, Shepherd K, Masters SL, Mehr S.   +6 more
europepmc   +1 more source

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

American Journal of Hematology, Volume 101, Issue 9, Page 2166-2176, September 2026.
ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA (n = 35) or alloHSCT (n = 31). Baseline characteristics
Saubia Fathima, Margaret Mei‐Kay Wong, Jesus Gonzalez‐Lugo, Susan M. Geyer, Ali Alsugair, Maria Sirenko, Kimberly J. Langer, Terra L. Lasho, Christy Finke, Jun Choi, Maher Abdul‐Hay, Gary Ho, Mark R. Litzow, Aasiya Matin, Urshila Durani, Mehrdad Hefazi, William J. Hogan, Mithun V. Shah, Aref Al‐Kali, Kebede H. Begna, Naseema Gangat, Antoine N. Saliba, Ronald S. Go, Tariq Kewan, Gabriel Bartoo, Jade Kutzke, Kristen McCullough, Kenneth J. Warrington, Megan Sullivan, Kaaren K. Reichard, Horatiu Olteanu, Hemant Murthy, Talha Badar, Yael Kusne, Jeanne Palmer, Saurabh Chhabra, Nathan Punwani, Mary Riwes, Joseph P. McGuirk, Elizabeth F. Krakow, Amelia Langston, Taxiarchis Kourelis, David Dingli, James Foran, Matthew J. Koster, Mrinal M. Patnaik, David B. Beck, Hassan B. Alkhateeb, Abhishek A. Mangaonkar   +48 more
wiley   +1 more source

Tocilizumab-induced inflammatory flare in Takayasu arteritis: a case report with exploratory mechanistic findings of Fcγ receptor involvement. [PDF]

Front Immunol
Shen N, Jin X, Lv P, Chen X, Xu X, Lu L, Han Y.   +6 more
europepmc   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

Refractory Relapsing-Remitting Adult-Onset Still's Disease in an Adolescent Female: A Rare Case Report. [PDF]

Clin Case Rep
Nafian T, Bhuiyan MMA, Aftab KA, Murshed KM, Azad MAK.   +4 more
europepmc   +1 more source

Vasopressor‐Associated Limb Ischemia Resulting in Quadruple Amputation in Suspected Septic Shock

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Vasopressor‐associated limb ischemia (VALI) is a rare but devastating complication of vasopressor therapy in septic shock. This case shows catastrophic four‐limb amputation in a 26‐year‐old obese male with suspected septic shock. This case illustrates the complex interplay between prolonged high‐dose vasopressor therapy, morbid obesity, and ...
Muni Rubens, Venkataraghavan Ramamoorthy, Krimal Shah, Ashley Rodriguez, Brian Murillo, Karelis Lopez Muniz, Anshul Saxena, Peter McGranaghan, Tina Sanjar   +8 more
wiley   +1 more source

Case Report: Tocilizumab in pediatric febrile infection-related epilepsy syndrome. [PDF]

Front Immunol
Pang L, Liu X, Sun S, Chen F, Lu H, Du Y, Li X.   +6 more
europepmc   +1 more source

Cardiovascular Immune‐Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta‐Summary of Case Reports

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Reports of immune checkpoint inhibitor (ICI) therapy‐associated immune‐related adverse events (irAEs) exhibit considerable heterogeneity, particularly when comparing data from clinical trials and real‐world observational studies. Methods We conducted a systematic review of real‐world observational studies (case reports and series ...
Shea‐Lee Godin, Tyler Kingma, Ashwin Pillai, Obada Kholoki, Agnes S. Kim   +4 more
wiley   +1 more source

Clinical Use of Interleukin-6 Blockade in Neuroimmunological Disorders. [PDF]

Noro Psikiyatr Ars
Erdal M, Arı A, Emekli AS, Yılmaz NÇ, Kürtüncü M.   +4 more
europepmc   +1 more source

A Review of Senescence‐Associated Secretory Phenotype‐Mediated Remodeling of the Tumor Microenvironment: Implications for Cancer Progression and Therapy

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Cellular senescence influences cancer progression through irreversible cell‐cycle arrest, immune surveillance, and paracrine signaling mediated by the senescence‐associated secretory phenotype (SASP). SASP comprises inflammatory cytokines, chemokines, growth factors, and matrix‐remodeling enzymes that regulate the tumor ...
Sneha Pallatt, Sibin Nambidi, Antara Banerjee, Surajit Pathak   +3 more
wiley   +1 more source